250 related articles for article (PubMed ID: 18331757)
1. Overexpression of CEACAM6 in borderline and invasive mucinous ovarian neoplasms.
Litkouhi B; Litkouhi B; Fleming E; Welch WR; Berkowitz RS; Birrer MJ; Mok SC
Gynecol Oncol; 2008 May; 109(2):234-9. PubMed ID: 18331757
[TBL] [Abstract][Full Text] [Related]
2. B7-H4 overexpression in ovarian tumors.
Tringler B; Liu W; Corral L; Torkko KC; Enomoto T; Davidson S; Lucia MS; Heinz DE; Papkoff J; Shroyer KR
Gynecol Oncol; 2006 Jan; 100(1):44-52. PubMed ID: 16256178
[TBL] [Abstract][Full Text] [Related]
3. Differential expression of protease activated receptor 1 (Par1) and pY397FAK in benign and malignant human ovarian tissue samples.
Grisaru-Granovsky S; Salah Z; Maoz M; Pruss D; Beller U; Bar-Shavit R
Int J Cancer; 2005 Jan; 113(3):372-8. PubMed ID: 15455382
[TBL] [Abstract][Full Text] [Related]
4. [Clinicopathologic analysis and expression of cyclin D1 and p53 of ovarian borderline tumors and carcinomas].
Shao HL; Shen DH; Xue WC; Li Y; Yu YZ
Zhonghua Fu Chan Ke Za Zhi; 2007 Apr; 42(4):227-32. PubMed ID: 17631760
[TBL] [Abstract][Full Text] [Related]
5. EZH2 supports ovarian carcinoma cell invasion and/or metastasis via regulation of TGF-beta1 and is a predictor of outcome in ovarian carcinoma patients.
Rao ZY; Cai MY; Yang GF; He LR; Mai SJ; Hua WF; Liao YJ; Deng HX; Chen YC; Guan XY; Zeng YX; Kung HF; Xie D
Carcinogenesis; 2010 Sep; 31(9):1576-83. PubMed ID: 20668008
[TBL] [Abstract][Full Text] [Related]
6. Integrin-linked kinase expression increases with ovarian tumour grade and is sustained by peritoneal tumour fluid.
Ahmed N; Riley C; Oliva K; Stutt E; Rice GE; Quinn MA
J Pathol; 2003 Oct; 201(2):229-37. PubMed ID: 14517840
[TBL] [Abstract][Full Text] [Related]
7. Morphological subtypes of ovarian carcinoma: a review with emphasis on new developments and pathogenesis.
McCluggage WG
Pathology; 2011 Aug; 43(5):420-32. PubMed ID: 21716157
[TBL] [Abstract][Full Text] [Related]
8. Differential gene expression profiles between tumor biopsies and short-term primary cultures of ovarian serous carcinomas: identification of novel molecular biomarkers for early diagnosis and therapy.
Bignotti E; Tassi RA; Calza S; Ravaggi A; Romani C; Rossi E; Falchetti M; Odicino FE; Pecorelli S; Santin AD
Gynecol Oncol; 2006 Nov; 103(2):405-16. PubMed ID: 16725184
[TBL] [Abstract][Full Text] [Related]
9. Alteration of BRCA-1 tumor suppressor gene expression in serous and mucinous ovarian neoplasms in the benign-borderline-malignant pathway.
Yousif HMA; Mohammed RAA
Curr Probl Cancer; 2019 Aug; 43(4):377-385. PubMed ID: 30446260
[TBL] [Abstract][Full Text] [Related]
10. Placental leucine aminopeptidase (P-LAP) and glucose transporter 4 (GLUT4) expression in benign, borderline, and malignant ovarian epithelia.
Shibata K; Kajiyama H; Mizokami Y; Ino K; Nomura S; Mizutani S; Terauchi M; Kikkawa F
Gynecol Oncol; 2005 Jul; 98(1):11-8. PubMed ID: 15907336
[TBL] [Abstract][Full Text] [Related]
11. Overexpression of epithelial cell adhesion molecule in primary, metastatic, and recurrent/chemotherapy-resistant epithelial ovarian cancer: implications for epithelial cell adhesion molecule-specific immunotherapy.
Bellone S; Siegel ER; Cocco E; Cargnelutti M; Silasi DA; Azodi M; Schwartz PE; Rutherford TJ; Pecorelli S; Santin AD
Int J Gynecol Cancer; 2009 Jul; 19(5):860-6. PubMed ID: 19574774
[TBL] [Abstract][Full Text] [Related]
12. Expression of HER2/neu, estrogen and progesterone receptors, CA 125 and CA19-9 on cancer cell membrane in patients with serous and mucinous carcinoma of the ovary.
Karaferic A; Jovanovic D; Jelic S
J BUON; 2009; 14(4):635-9. PubMed ID: 20148455
[TBL] [Abstract][Full Text] [Related]
13. Fascin and EMMPRIN expression in primary mucinous tumors of ovary: a tissue microarray study.
Alici O; Kefeli M; Yildiz L; Baris S; Karagoz F; Kandemir B
Pathol Res Pract; 2014 Dec; 210(12):934-8. PubMed ID: 25155376
[TBL] [Abstract][Full Text] [Related]
14. Significance of cell cycle regulatory proteins as malignant and prognostic biomarkers in ovarian epithelial tumors.
Lee YH; Heo JH; Kim TH; Kang H; Kim G; Kim J; Cho SH; An HJ
Int J Gynecol Pathol; 2011 May; 30(3):205-17. PubMed ID: 21464733
[TBL] [Abstract][Full Text] [Related]
15. Overexpression and clinical significance of carcinoembryonic antigen-related cell adhesion molecule 6 in colorectal cancer.
Kim KS; Kim JT; Lee SJ; Kang MA; Choe IS; Kang YH; Kim SY; Yeom YI; Lee YH; Kim JH; Kim KH; Kim CN; Kim JW; Nam MS; Lee HG
Clin Chim Acta; 2013 Jan; 415():12-9. PubMed ID: 22975528
[TBL] [Abstract][Full Text] [Related]
16. CEACAM6 as detected by the AP11 antibody is a marker notable for mucin-producing adenocarcinomas.
Lee OJ; Son SM; Hong KP; Lee YM; Kim MY; Choi JW; Lee SJ; Song YJ; Kim HS; Kim WJ; Shin SO; Song HG
Virchows Arch; 2015 Feb; 466(2):151-9. PubMed ID: 25427744
[TBL] [Abstract][Full Text] [Related]
17. Loss of cables, a novel gene on chromosome 18q, in ovarian cancer.
Dong Q; Kirley S; Rueda B; Zhao C; Zukerberg L; Oliva E
Mod Pathol; 2003 Sep; 16(9):863-8. PubMed ID: 13679449
[TBL] [Abstract][Full Text] [Related]
18. Immunohistochemical characterization of mullerian mucinous borderline tumors: possible histogenetic link with serous borderline tumors and low-grade endometrioid tumors.
Yasunaga M; Ohishi Y; Oda Y; Misumi M; Iwasa A; Kurihara S; Nishimura I; Okuma E; Kobayashi H; Wake N; Tsuneyoshi M
Hum Pathol; 2009 Jul; 40(7):965-74. PubMed ID: 19269675
[TBL] [Abstract][Full Text] [Related]
19. Expression of glucose transporter protein 1 and p63 in serous ovarian tumor.
Cai Y; Zhai JJ; Feng BB; Duan XZ; He XJ
J Obstet Gynaecol Res; 2014 Jul; 40(7):1925-30. PubMed ID: 25056472
[TBL] [Abstract][Full Text] [Related]
20. [Expression of mesothelin mRNA and protein in ovarian carcinomas].
Bi SN; Dai SZ; Yao Q; Che YC; Wang N
Zhonghua Zhong Liu Za Zhi; 2008 Apr; 30(4):288-91. PubMed ID: 18788634
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
